Ascletis Pharma Inc. expects to record (i) a total revenue ranging from RMB 46.0 million to RMB 47.0million for the six months ended June 30, 2023, representing an increase of approximately 20.4% to 23.0% from approximately RMB 38.2 million for the six months ended June 30, 2022; and (ii) a net loss attributable to the owners of the Company ranging from RMB 14.0 million to RMB 22.0 million for the six months ended June 30, 2023, representing a decrease of approximately 84.1% to 75.0% as compared to that for the six months ended June 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 HKD | -1.10% | -15.09% | -38.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.36% | 117M | |
+2.22% | 93.91B | |
-1.32% | 38.4B | |
-13.44% | 32.61B | |
+76.30% | 28.2B | |
-13.11% | 15.91B | |
+0.68% | 14.22B | |
-12.06% | 11.54B | |
+185.28% | 10.74B | |
-53.00% | 9.47B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2023